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Initiation of cell-mediated immune responses requires pro- 
cessing of intracellular pathogens into peptide fragments 
and presentation of these fragments to effector T cells. 
In the past few years, considerable progress has been 
made in understanding the molecular mechanisms under- 
lying antigen processing and presentation. In particular, 
recent work has led to an understanding of the function 
of HLA-DM (DM), a key player in antigen presentation, 
whose importance was first appreciated only 1 year ago. 
Antigen Processing in Prelysosomal 
Compartments: The Basics 
Major histocompatibility complex (MHC) proteins are re- 
sponsible for binding and presenting antigen-derived pep- 
tides to T cells (Germain, 1994). Unlike class I MHC mole- 
cules, which bind peptides derived from cytosolic antigens 
and present them to CDB-restricted T cells, class II MHC 
molecules generally bind peptides generated by proteoly- 
sis of exogenous antigens in endocytic compartments and 
present these peptides to CDCrestricted antigen-specific 
T cells. Since class I and class II molecules coexist in 
the endoplasmic reticulum (ER) and are each capable of 
binding antigenic peptides, it was proposed that a mecha- 
nism must exist to “protect” the peptide-binding groove of 
class II molecules in the ER from occupancy by cytosoli- 
tally produced endogenous peptides. In 1990, it was dem- 
onstrated that the class II-associated invariant chain (Ii) 
performed this function (Roche and Cresswell, 1990). Ii 
is a type II transmembrane glycoprotein that associates 
with newly synthesized class II a and p chains in the ER. 
Association with Ii prevents the binding of peptides to class 
II molecules (and vice versa) and newly synthesized apli 
complexes are devoid of antigenic peptides; thus, Ii pre- 
vents newly synthesized class II molecules from sampling 
ER peptides. 
In addition to its role in blocking premature peptide bind- 
ing to class II molecules, Ii contains an extremely efficient 
endosomalllysosomal targeting motif in its amino-terminal 
cytosolic domain (Bakke and Dobberstein, 1990), and this 
signal is responsible for delivery of newly synthesized 
class II abli complexes to intracellular antigen-processing 
compartments. Once in these compartments, class ll-asso- 
ciated Ii is degraded by proteinases such as cathepsin B 
and cathepsin D. Stepwise proteolysis of Ii leads to forma- 
tion of distinct class II-associated Ii fragments that have 
been well characterized biochemically (Blum and Cress- 
well, 1988). Following dissociation of Ii fragments from 
class II molecules, antigenic peptides are able to bind to 
newly liberated class II ah heterodimers. The resulting 
class II a[3-peptide complex is then transported to the 
plasma membrane for recognition by CDCrestricted T 
cells, thereby completing the antigen processing and pre- 
sentation cycle. 
APC Mutants Point to Additional Players in MHC 
Class II Peptide Loading 
The rate of stable peptide association with purified class 
II a0 heterodimers in vitro is extremely slow as compared 
with the rapid acquisition of peptide by class II molecules 
in vivo, suggesting that a mechanism exists in vivo to load 
peptides onto class II molecules efficiently. Characteriza- 
tion of several mutant antigen-presenting cell (APC) lines 
confirmed this hypothesis (Mellins et al., 1990). Although 
the class II structural genes in these mutant cells were not 
themselves altered, certain class II conformation-specific 
monoclonal antibody epitopes were absent. In addition, 
class II molecules from these mutant APCs were unstable 
and dissociated into free a and p chains in the presence of 
SDS, whereas most class II molecules from their wild-type 
progenitors did not. Most importantly, these mutants were 
incapable of processing and presenting exogenously 
added foreign protein antigens to T cells, although they 
were perfectly capable of binding and presenting the pre- 
processed peptide fragments of these antigens. 
Since SDS stability of class II molecules has been sug- 
gested to represent stable acquisition of peptides by up 
heterodimers (Sadegh-Nasseri and Germain, 1991), it 
seemed reasonable to assume that the antigen presenta- 
tion defect in mutant APCs was a consequence of the 
inability of their class II molecules to bind peptides. It was 
subsequently determined that most class II molecules 
from these mutant cells did in fact contain peptides, but, 
unlike the diverse array of peptides found associated with 
wild-type class II molecules, essentially all of the peptides 
were derived from proteolytic fragments of Ii (Riberdy et 
al., 1992; Sette et al., 1992). These peptides were dubbed 
CLIP, for class II-associated invariant chain peptides, and 
represent a nested set of peptides corresponding to Ii 
amino acid residues 81-104. Because normal APCs also 
contain class II ab-CLIP complexes, but in much smaller 
amounts, it was appreciated that CLIP represented a nor- 
mal biosynthetic intermediate in the degradation of Ii from 
apli complexes. Consequently, it was proposed that the 
defect in mutant APCs involved their inability to generate 
antigenic peptides, their inability to exchange CLIP for 
antigenic peptides, or their inability to direct apli com- 
plexes (or antigenic peptides) into the proper peptide- 
loading compartments. 
Elegant genetic studies established that mutant APCs 
in fact contained lesions in DM, originally identified as a 
novel gene of unknown function that mapped to the class 
II region of the MHC between HLA-DP and HLA-DQ (Morris 
et al., 1994; Fling et al., 1994). Like conventional class II 
molecules, DM is a transmembrane glycoprotein com- 
posed of an a chain and a p chain. The homology of DM 
with conventional class’11 proteins is only marginal, how- 
ever, as DM appears to be almost as closely related to 
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class I molecules as to class II molecules. When mutant 
APCs containing lesions in DMa or DMj3 genes were 
transfected with the corresponding wild-type cDNAs, the 
phenotype reverted to that of the wild-type progenitor cells 
and they were now able to present foreign antigens to T 
cells. However, the mechanism by which DM allowed class 
II molecules to adopt a proper conformation and to bind 
and present processed antigen to T cells remained elusive. 
DM Induces CLIP Dissociation and Peptide Binding 
to MHC Class II Molecules 
Within the last month, three different papers have demon- 
strated that DM catalyzes the dissociation of CLIP from 
class II aj3-CLIP complexes (Sloan et al., 1995; Denzin 
and Cresswell, 1995; Sherman et al., 1995). Following 
CLIP removal, class II a5 dimers are capable of effectively 
binding antigenic peptides, rapidly leading to generation 
of SDS-stable class jl molecules. Thus, the phenotype of 
the APC mutants appears to be due to an inability to re- 
move CLIP from class II molecules. This effect was ob- 
served using DM isolated from several different sources 
and similar resultswere obtained with both murine and 
human class II molecules. In agreement with earlier stud- 
ies of peptide binding to purified class II molecules, the 
enhancement in the rate of class II peptide binding induced 
by DM is likely to be a consequence of CLIP removal from 
the class II peptide-binding groove. However, evidence 
suggesting that DM facilitates peptide binding to empty 
class II molecules has also been obtained (Denzin and 
Cresswell, 1995) although it is premature to conclude 
from such experiments that DM performs a peptide- 
binding enhancement function independent of its CLIP- 
dissociation function. 
The steady-state amount of DM in professional APCs 
is thought to be quite low and DM has a remarkably long 
half-life in vivo, suggesting that DM may functional catalyti- 
cally(Denzinetal., 1994). Experimentsdemonstrating that 
substoichiometric levels of DM were sufficient to enhance 
SDS stability of class II molecules support this hypothesis 
(Karlsson et al., 1994; Denzin and Cresswell, 1995). An 
alternative theory postulated for the function of DM, 
namely that DM acted as a CLIP “sink,” capable of binding 
CLIP that has dissociated from aj3-CLIP complexes, is 
not consistent with these data. It appears likely, therefore, 
that one molecule of DM can lead to release of many CLIPS 
from aj3-CLIP complexes. 
Does DM Enhance Release of Non-CLIP Peptides 
from MHC Class II Molecules? 
In addition to the ability to remove CLIP from aj3-CLIP 
complexes, DM can also catalyze the removal of non-CLIP 
peptides from class II molecules and can facilitate peptide 
binding to class II molecules synthesized in Ii-negative 
cells (Sloan et al., 1995). Similarly, transfection with DM 
increases the amount of SDS-stable I-Ak molecules gener- 
ated, even in cells not expressing Ii in vivo (Karlsson et 
al, 1994). These results strongly suggest that aj3-CLIP 
complexes are not the only substrates for DM. By contrast, 
DM had very little effect on SDS stability of DR a6 dimers 
isolated from wild-type B-LCL (Denzin and Cresswell, 1995). 
In this study, however, the class II molecules were mature, 
and any unstable class II-peptide complexes may have 
become stabilized by endogenous DM long before their 
isolation. A reasonable hypothesis that can reconcile both 
types of data is that DM catalyzes the release of prebound 
peptides from class II molecules, allowing DM to act as 
a peptide “editor,” ensuring that only long-lived class II- 
peptide complexes escape to the cell surface (Sloan et 
al., 1995). This hypothesis is also consistent with the idea 
that DM catalyzes the release of peptides that do not pro- 
duce SDS-stable a6 dimers, although this requires further 
substantiation. 
DM Functions lntracellularly in 
Antigen-Processing Compartments 
DM is maximally effective at pH ranges of 4.5-6, condi- 
tions that approximate those found in antigen-processing 
compartments. When the cellular localization of DM in B 
lymphoblastoid cell lines was investigated by immunoelec- 
tron microscopy, it was found to colocalize with the major- 
ity of conventional class II molecules in a prelysosomal 
compartment, termed the MHC class II compartment, or 
MIIC (Peters et al., 1991; Sanderson et al., 1994; Karlsson 
et al., 1994; Nijman et al., 1995). Similar, if not identical, 
prelysosomal compartments have been observed in B cell 
lines, melanoma cell lines, activated macrophages, and 
dendritic cells. The exact relationship between the MIIC 
originally defined in B lymphoblastoid cell lines and these 
other prelysosomal antigen processing compartments still 
needs to be resolved; however, for simplicity, all class II 
moleculeenriched prelysosomal antigen-processing com- 
partments will be referred to as MIIC. These compartments 
are located late in the endocytic pathway, and most class 
II aj3li complexes appear to be targeted to these compart- 
ments directly from the rrans-Golgi network. Several stud- 
ies published within the last year strongly implicate these 
compartments as the predominant sites of antigenic pep 
tide loading to newly synfhesized class II molecules, al- 
though peptide loading in earlier endocytic compartments 
is also possible. 
Unlike conventional class II molecules, DM does not 
significantly associate with Ii and transport of DM to MllCs 
is independent of Ii expression (Denzin et al., 1994; Karls- 
son et al., 1994). The recent finding that MIIC targeting 
information resides in a tyrosine-based motif in the DM 6 
chain cytosolic domain is in excellent agreement with 
these findings (Marks et al., 1995). Almost no DM is found 
on the plasma membrane, consistent with its intracellular 
role in antigen presentation. 
Model of DM Function in 
Antigen-Processing Compartments 
A cartoon illustrating the role of DM in facilitating peptide 
binding and dissociation of CLIP from aj&CLIP complexes 
in MIIC is shown in Figure 1. Class II a6li complexes are 
transported from the rrans-Golgi network to an early MIIC. 
Since few Ii epitopes are present in conventional MIIC, it 
is likely that a6li complexes are transported to this com- 
partment before eventual transport to MIIC. In this model, 
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Figure 1. Model of HtA-DM Function in Antigen-Processing Compartments. 
Following the delivery of class II af3li complexes from the trans-Golgi network to an as yet uncharacterized early MIIC (where Ii proteolysis is 
initiated), ab-CLIP complexes are targeted to MIIC compartments. Once in MIIC, CLIP is removed from the class II up-CLIP complex by a 
DMdependent process involving the following steps. The affinity of DM for UP-CLIP (I) results in the formation of an aD-CLIPIDM complex (II). 
The binding of DM induces a conformational change in up-CLIP and leads to dissociation of CLIP from the complex (Ill). Following CLIP dissociation, 
antigenic peptides bind to empty class II a!3 dimers that are stabilized by association with DM (IV). Antigenic peptide binding results in aconformational 
change in the ap dimer/DM complex and leads to dissociation of DM from the complex (V). Although DM is retained in the MIIC to catalyze the 
release of CLIP from additional ao-CLIP complexes, class II ab-peptide complexes leave the MIIC in transport vesicles bound for the cell surface. 
Ii proteolysis begins in the early MIIC, leaving only ap- to facilitate peptide binding, SDS-stable class II ap dimer 
CLIP complexes to be transported to MIIC. formation, and antigen presentation. 
Once in MIIC, interaction of DM with the a&CLIP com- 
plex facilitates release of CLIP and allows antigenic pep- 
tide binding to the class II up dimer. One can imagine 
that the facilitation of peptide loading by DM occurs in the 
following sequence. DM binds to class II a@CLIP com- 
plexes, inducing a conformational change that results in 
rapid release of CLIP from the class II peptide-binding 
groove. DM remains associated with the empty class II 
molecule until a new peptide binds, preventing aggrega- 
tion of empty afi dimers. Antigenic peptides present in 
MIIC then bind to the recently emptied ap dimer and, under 
the low pH conditions of MIIC, “lock” the class II ab dimer 
into a conformation that is unfavorable for DM association. 
Since DM appears to function catalytically, released DM 
molecules are available for reuse in MIIC. Finally, the class 
II ap-peptide complex receives signals (perhaps a conse- 
quence of peptide-induced conformational changes in the 
af3 dimer itself) to exit the MIIC and enter a transport vesi- 
cle, which eventually fuses with the plasma membrane to 
present the class II-bound antigenic peptide to T cells. 
Is DM Required for Antigen Presentation Function? 
Since the function of DM is to catalyze the removal of 
CLIP from ab-CLIP complexes, one might expect that DM 
would not be necessary in situations in which CLIP is only 
weakly associated with class II molecules. In agreement 
with this hypothesis are recent results demonstrating that 
the ability of DM to enhance antigen presentation and 
SDS-stable a0 dimer formation is allele dependent 
(Brooks et al., 1994; Stebbins et al., 1995). In addition, 
there was good correlation between the requirement for 
DM to enhance antigen presentation and the stability of 
particular class II ab-CLIP complexes; alleles in which 
CLIP was very tightly bound to class II molecules required 
DM for efficient antigen presentation, whereas alleles in 
which CLIP was not tightly bound did not. Thus, the ease 
with which CLIP can dissociate from a@CLIP complexes 
can be inversely correlated with the requirement for DM 
What Is the Mechanism Behind the Function of DM? 
Given the ability of DM to catalyze the release of CLIP 
from ab-CLIP complexes, it seems reasonable to assume 
that DM binds to either CLIP or the class II ap dimer. 
However, no biochemical association between DM and 
CLIP or class II molecules has yet been demonstrated. 
Nevertheless, the isolation and characterization of an 
HLA-DR (DR) a chain mutant cell line that has an identical 
phenotype to the DM mutant APCs further supports the 
speculation that DM binds directly to class II molecules 
(Mellins et al., 1994). The DR a chain mutant possesses 
an additional glycosylation site that has been postulated 
to interfere with normal class II aB dimer-DM interactions, 
thereby leading to a DM mutant phenotype. Consistent 
with this hypothesis are experiments demonstrating that 
the in vitro effects of DM are not observed when class II 
molecules isolated from the DR a chain mutant APC were 
used as substrates (Sloan et al., 1995). In addition, an 
antibody that recognizes the amino-terminal region of 
CLIP can prevent the DM-mediated peptide loading of ap- 
CLIP complexes (Denzin and Cresswell, 1995), lending 
additional evidence in favor of a direct ab-CLIPIDM inter- 
action. 
One particularly puzzling feature of DM is that it appears 
to be able to discriminate between class II aB-CLIP com- 
plexes and other ag-peptide complexes. Crystallographic 
evidence suggests that CLIP is bound to the peptide- 
binding groove of ap dimers like conventional antigenic 
peptides. The finding that ab-CLIP complexes are unsta- 
ble in SDS, whereas most other ap-peptide complexes 
are not, argues that SDS stability may actually be the best 
indicator of whether a given ap-peptide complex can 
serve as a substrate for DM or not. Since CLIP binds with 
high affinity to many class II alleles, it seems likely that 
SDS stability does not correlate with peptide binding af- 
finity. Clearly, more work is required to understand the 
relationship between the SDS-unstable phenotype of af3- 
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CLIP complexes and their ability to serve as a substrate 
for DM. 
It is interesting to speculate that DM is acting in the 
capacity of a true molecular chaperone, binding to class 
II-peptide complexes that are relatively unstable and re- 
taining them in antigen-processing compartments until 
peptides capable of inducing SDS-stable a&peptide con- 
formations are bound. Since class II molecules aggregate 
in the absence of peptides (Stern and Wiley, 1992; Ger- 
main and Rinker, 1993), perhaps DM protects empty up 
dimers from aggregation while they are waiting for anti- 
genie peptides to bind. In this model, DM would be acting 
in a similar manner to the MHC class I chaperone calnexin 
that retains class I molecules in the ER until peptide bind- 
ing occurs. 
Conclusion 
The mechanisms involved in antigen processing and pre- 
sentation have begun to be unravelled in the past few 
years. Although the identification of Ii groove-blocking abil- 
ity helped explain the finding that cytosolic peptide anti- 
gens were not efficiently presented by class II molecules, 
it led to the question of how to get rid of Ii once this task 
was completed. Now that DM has been shown to be re- 
sponsible for Ii CLIP dissociation (and perhaps the dissoci- 
ation of other unstable peptides from class II molecules), 
we have a new problem to address; namely, how does a 
protein like DM distinguish “bad” class II-peptide com- 
plexes (such as a@CLIP complexes) from “good” stable 
class II-peptide complexes? If the progress of the last few 
years is any indication, we should have our answer shortly. 
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